Valentine Jehl

2.1k total citations · 1 hit paper
23 papers, 1.1k citations indexed

About

Valentine Jehl is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Valentine Jehl has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Valentine Jehl's work include Lung Cancer Research Studies (9 papers), Neuroendocrine Tumor Research Advances (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Valentine Jehl is often cited by papers focused on Lung Cancer Research Studies (9 papers), Neuroendocrine Tumor Research Advances (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Valentine Jehl collaborates with scholars based in Switzerland, United States and Germany. Valentine Jehl's co-authors include James C. Yao, Judith Klimovsky, Marc Peeters, John D. Hainsworth, Éric Baudin, Robert Winkler, Marianne Pavel, Edward M. Wolin, David Lebwohl and Kjell Öberg and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Valentine Jehl

23 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

2011 767 citations Marianne Pavel, John D. Hainsworth et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Valentine Jehl Switzerland	11	809	740	536	236	129	23	1.1k
Robert Winkler United States	16	895 1.1×	823 1.1×	529 1.0×	226 1.0×	140 1.1×	59	1.3k
Aejaz Nasir United States	17	896 1.1×	754 1.0×	587 1.1×	262 1.1×	116 0.9×	39	1.3k
Eileen Regan United States	16	620 0.8×	361 0.5×	255 0.5×	200 0.8×	238 1.8×	34	907
Susanne M. Hooshmand United States	9	711 0.9×	450 0.6×	314 0.6×	156 0.7×	142 1.1×	12	876
Lauren K. Brais United States	17	902 1.1×	478 0.6×	271 0.5×	246 1.0×	99 0.8×	39	1.3k
C. Lombard Bohas France	6	1.7k 2.1×	1.7k 2.3×	1.2k 2.2×	434 1.8×	205 1.6×	17	2.2k
Daria Handkiewicz-Junak Poland	22	324 0.4×	284 0.4×	146 0.3×	226 1.0×	173 1.3×	69	1.7k
T. Barnes Canada	12	610 0.8×	224 0.3×	153 0.3×	173 0.7×	256 2.0×	28	988
Robert F. Marschke United States	16	578 0.7×	257 0.3×	156 0.3×	198 0.8×	275 2.1×	39	863
Satoshi Igawa Japan	18	755 0.9×	281 0.4×	164 0.3×	299 1.3×	597 4.6×	100	1.2k

Countries citing papers authored by Valentine Jehl

Since Specialization

Citations

This map shows the geographic impact of Valentine Jehl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Valentine Jehl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Valentine Jehl more than expected).

Fields of papers citing papers by Valentine Jehl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Valentine Jehl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Valentine Jehl. The network helps show where Valentine Jehl may publish in the future.

Co-authorship network of co-authors of Valentine Jehl

This figure shows the co-authorship network connecting the top 25 collaborators of Valentine Jehl. A scholar is included among the top collaborators of Valentine Jehl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Valentine Jehl. Valentine Jehl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hauser, Stephen L., Jeffrey A. Cohen, J. de Sèze, et al.. (2025). Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis. Neurology and Therapy. 14(5). 1975–1992. 2 indexed citations

Grewal, Dilraj S., et al.. (2023). Imaging Features of Retinal Vasculitis and/or Retinal Vascular Occlusion after Brolucizumab Treatment in the Postmarketing Setting. SHILAP Revista de lepidopterología. 4(1). 100361–100361. 2 indexed citations

Bove, Riley, Maria Pia Amato, Ruth Dobson, et al.. (2023). Pregnancy Outcomes in Patients With MS Following Exposure to Ofatumumab: Updated Results From the Novartis Safety Database (P9-3.014). Neurology. 100(17_supplement_2). 2 indexed citations

Rufibach, Kaspar, Claudia Schmoor, Valentine Jehl, et al.. (2022). Comparison of Adverse Event Risks in Randomized Controlled Trials with Varying Follow-Up Times and Competing Events: Results from an Empirical Study. Statistics in Biopharmaceutical Research. 15(4). 767–780. 2 indexed citations

Hauser, Stephen L., Anne H. Cross, Kevin Winthrop, et al.. (2022). Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Multiple Sclerosis Journal. 28(10). 1576–1590. 45 indexed citations

Bar‐Or, Amit, J. de Sèze, Jorge Correale, et al.. (2021). Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis (RMS) Patients from the Phase 3 ASCLEPIOS I and II Trials (1300). Neurology. 96(15_supplement). 9 indexed citations

Schmoor, Claudia, Jan Beyersmann, Kaspar Rufibach, et al.. (2021). Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)—estimation of adverse event risks. Trials. 22(1). 420–420. 13 indexed citations

Lebwohl, Mark, Atul Deodhar, C.E.M. Griffiths, et al.. (2021). The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up. British Journal of Dermatology. 185(5). 935–944. 37 indexed citations

Hollaender, Norbert, et al.. (2019). Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis. Biometrical Journal. 62(3). 658–669. 2 indexed citations

10.

Dummer, Reinhard, Dirk Schadendorf, Paolo A. Ascierto, et al.. (2016). Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.. Journal of Clinical Oncology. 34(15_suppl). 9500–9500. 24 indexed citations

11.

Besse, Benjamin, Natasha B. Leighl, Jaafar Bennouna, et al.. (2013). Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer. Annals of Oncology. 25(2). 409–415. 53 indexed citations

12.

Eberhardt, Wilfried, Paul Mitchell, Joan H. Schiller, et al.. (2013). Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer. Investigational New Drugs. 32(1). 123–134. 4 indexed citations

13.

Yao, James C., Alexandria T. Phan, Valentine Jehl, Gaurav Shah, & Funda Meric‐Bernstam. (2013). Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience. Cancer Research. 73(5). 1449–1453. 68 indexed citations

14.

Papadimitrakopoulou, Vassiliki A., Jean‐Charles Soria, Annette Jappe, et al.. (2012). Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 7(10). 1594–1601. 28 indexed citations

15.

Yao, James C., Stefano Ricci, Robert Winkler, Valentine Jehl, & Marianne Pavel. (2011). Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2.. Journal of Clinical Oncology. 29(15_suppl). 4011–4011. 5 indexed citations

16.

Pavel, Marianne, John D. Hainsworth, Éric Baudin, et al.. (2011). Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. The Lancet. 378(9808). 2005–2012. 767 indexed citations breakdown →

17.

Yao, James C., John D. Hainsworth, Éric Baudin, et al.. (2011). Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2).. Journal of Clinical Oncology. 29(4_suppl). 159–159. 18 indexed citations

18.

Soria, J.C., Jaafar Bennouna, Natasha B. Leighl, et al.. (2009). 9174 Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). European Journal of Cancer Supplements. 7(2). 558–559. 2 indexed citations

19.

Piga, Antonio, Kamila Kébaïli, Renzo Galanello, et al.. (2008). Cumulative Efficacy and Safety of 5-Year Deferasirox (Exjade®) Treatment in Pediatric Patients with Thalassemia Major: A Phase II Multicenter Prospective Trial. Blood. 112(11). 5413–5413. 8 indexed citations

20.

Piedbois, Pascal, D. Serin, Franck Priou, et al.. (2006). Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology. 18(1). 52–57. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact